Replies to post #110101 on Biotech Values

[DewDiligence]

From an investment standpoint, I don’t place much importance on the individual HCV mutations—please see #msg-52754094.

[DewDiligence]

JNJ starts phase-1 trial of HCV nuke, TMC649128, which was licensed from Medivir:

http://finance.yahoo.com/news/Medivir-Announces-Start-of-prnews-4253261914.html?x=0&.v=2